News

Our Healthcare News

AxoGen, Inc. Announces Proposed Public Offering of Common Stock

ALACHUA, Florida—(GLOBE NEWSWIRE)—AxoGen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for the repair of peripheral nerve damage, announced today that…  

Nov 15 2017

EUSA Pharma and AVEO Oncology Announce First Commercial Launch of FOTIVDA (tivozanib)

HEMEL HEMPSTEAD, England & CAMBRIDGE, Massachusetts. – – EUSA Pharma and AVEO Oncology (NASDAQ: AVEO) today announced the first commercial launch of FOTIVDA® (tivozanib) with…  

Nov 15 2017

Otsuka and Proteus Announce First U.S. FDA Approval of a Digital Medicine System:  ABILIFY MYCITE

TOKY, Japan and REDWOOD CITY, California– Otsuka Pharmaceutical Co., Ltd.  (Otsuka) and Proteus Digital Health (Proteus) today announce that the United States Food and Drug…  

Nov 14 2017

Grupo Biotoscana Acquires Laboatorio DOSA

Montevideo, Uruguay - - GBT-Grupo Biotoscana (B3: GBIO33), a leading biopharmaceutical company in Latin America, today announced the acquisition of Laboratorio DOSA S.A., a specialty…  

Nov 13 2017

Biotoscana Announces Launch of ABRAXANE/ABRAXUS in Brazil and Mexico

MONTEVIDEO, Uruguay—BIOTOSCANA INVESTMENTS S.A. (“Company” or “GBT”) (B3: GBIO33), a leading biopharmaceutical company in Latin America, announces to its shareholders and the market in general…  

Nov 01 2017

EW Healthcare Partners Announces the Appointment of Three Senior Executives

NEW YORK, New York—EW Healthcare Partners (“EW”), a leading healthcare growth equity firm with a global investment practice, has announced the addition of three senior…  

Oct 18 2017

AxoGen, Inc. Receives David J. Gury Company of the Year Award from BioFlorida

ALACHUA, Florida (GLOBE NEWSWIRE)—AxoGen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, has received the BioFlorida David…  

Oct 18 2017

Bill Burns Nominated for Election to Molecular Partners’ Board of Directors

Zurich-Schlieren, SWITZERLAND—Molecular Partners AG (SIX: MOLN), a clinical-stage biopharmaceutical company developing a new class of drugs known as DARPin® therapies*, today announced that its Board…  

Oct 03 2017

Grupo Biotoscana and EISAI Sign Licensing Agreement for Four Oncology & Neurology Products in LatAm

MONTEVIDEO, Uruguay and WOODCLIFF LAKE, New Jersey—GBT-Grupo Biotoscana (B3: GBIO33), a leading biopharmaceutical company in Latin America, today announced that it has entered into an…  

Oct 03 2017